RxDoctor Payments Data

Seema Patel, NP

Family · Burlington, NCNPI 1487356978

Payments from drug & device makers

$1,199in general payments, 2019–2025

Across 46 payments — averaging $26.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$321
  • Medtronic$309
  • Globus Medical$190
  • Collegium Pharmaceutical, Inc.$95
  • Forte Bio-pharma LLC$38
  • Novo Nordisk$37
  • plus $207 from 10 others

What the payments were for

  • Food & beverage$1,199100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,199 in reported general payments places this provider in the 70th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$45,915
Medicare patients
78
Services billed
1,337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin34$31,120
MounjaroTirzepatide24$28,689
OzempicSemaglutide21$22,368
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$22,150
LinzessLinaclotide19$20,277
TrulicityDulaglutide15$19,599
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen496$17,399
Xtampza ErOxycodone Myristate11$8,349
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl22$6,434
Naloxone Hcl103$6,301
Breo ElliptaFluticasone/Vilanterol11$5,270
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen137$4,537
Oxycodone Hcl187$4,150
Buprenorphine29$3,569
SymbicortBudesonide/Formoterol Fumarate12$2,847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$19$48,28839 claims
Boehringer IngelheimJardiance$20$31,12034 claims
Novo NordiskOzempic$37$22,36821 claims
AbbVieLinzess$321$20,27719 claims
Collegium Pharmaceutical, Inc.Xtampza Er$95$8,34911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,522 family providers in North Carolina.

Other family in Burlington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →